JP2024540147A - サルベコウイルスに対するモノクローナル抗体の中和 - Google Patents

サルベコウイルスに対するモノクローナル抗体の中和 Download PDF

Info

Publication number
JP2024540147A
JP2024540147A JP2024525544A JP2024525544A JP2024540147A JP 2024540147 A JP2024540147 A JP 2024540147A JP 2024525544 A JP2024525544 A JP 2024525544A JP 2024525544 A JP2024525544 A JP 2024525544A JP 2024540147 A JP2024540147 A JP 2024540147A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540147A5 (enExample
Inventor
マンチーニ、ニカシオ
クレメンティ、ニコラ
クレメンティ、マッシモ
クリスクオロ、エレナ
システィ、ソフィア
リベラ、マルティーナ
Original Assignee
オスペダーレ サン ラファエレ エス．アール．エル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オスペダーレ サン ラファエレ エス．アール．エル filed Critical オスペダーレ サン ラファエレ エス．アール．エル
Publication of JP2024540147A publication Critical patent/JP2024540147A/ja
Publication of JP2024540147A5 publication Critical patent/JP2024540147A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024525544A 2021-10-29 2022-07-20 サルベコウイルスに対するモノクローナル抗体の中和 Pending JP2024540147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21205626.1 2021-10-29
EP21205626.1A EP4174083A1 (en) 2021-10-29 2021-10-29 Neutralizing monoclonal antibodies against sarbecoviruses
PCT/IB2022/056706 WO2023073441A1 (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses

Publications (2)

Publication Number Publication Date
JP2024540147A true JP2024540147A (ja) 2024-10-31
JP2024540147A5 JP2024540147A5 (enExample) 2025-07-31

Family

ID=78414544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525544A Pending JP2024540147A (ja) 2021-10-29 2022-07-20 サルベコウイルスに対するモノクローナル抗体の中和

Country Status (6)

Country Link
EP (2) EP4174083A1 (enExample)
JP (1) JP2024540147A (enExample)
AU (1) AU2022374853A1 (enExample)
CA (1) CA3235310A1 (enExample)
IL (1) IL312392A (enExample)
WO (1) WO2023073441A1 (enExample)

Also Published As

Publication number Publication date
EP4423124A1 (en) 2024-09-04
CA3235310A1 (en) 2023-05-04
EP4174083A1 (en) 2023-05-03
IL312392A (en) 2024-06-01
WO2023073441A1 (en) 2023-05-04
AU2022374853A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
Gai et al. A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential
CN111647076B (zh) 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用
AU2013229488B2 (en) Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
Collarini et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients
CN110684102B (zh) 一种sftsv检测试剂盒
Khan et al. Cross-neutralizing anti-HIV-1 human single chain variable fragments (scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library
US20240182549A1 (en) Peptides and antibody fusions that bind to sars-cov-2 and methods of using same
CN115515976A (zh) 冠状病毒抗体
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
JP2013505236A (ja) Ｈｉｖ−１抗体
Chen et al. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants
JP2008532559A (ja) ウイルス感染の治療及び予防又は治療及び予防の改善
CN103224559B (zh) 人源hiv广谱中和抗体a16及其相关生物材料与应用
JP2024540147A (ja) サルベコウイルスに対するモノクローナル抗体の中和
WO2021105669A1 (en) Antibodies
Pavan et al. Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants
CN102190726B (zh) 一种人源HIV抗体的Fab片段及其编码基因与应用
US20240166727A1 (en) Human neutralizing antigen specific proteins for spike-rbd of sars-cov-2
Li et al. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies
CN101198374B (zh) 具有抗hiv中和活性的抗体或其片段
CN107383190A (zh) 人源抗HIVgp41特异性抗体及其应用
TW202346329A (zh) 冠狀病毒之特異性抗體及其用途
IL278955A (en) Antibodies against sars cov-2
CN121335920A (zh) 靶向HIV Env上的CD4结合位点的广谱中和抗体
CN119371521A (zh) 一种广谱抗新型冠状病毒SARS-CoV-2的纳米抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428